A study by Swiderek-Matysiak et al. found no significant differences in CSF CXCL13 between MS patients and a control group comprising systemic inflammatory diseases with CNS involvement, cerebrovascular diseases, and other non-inflammatory neurological diseases [30]. This evidence concerns the gene CXCL13 and myeloid sarcoma.